Skip to main content
Lobe Sciences Ltd. logo

Lobe Sciences Ltd. — Investor Relations & Filings

Ticker · LOBE CSE Manufacturing
Filings indexed 206 across all filing types
Latest filing 2021-12-24 Regulatory Filings
Country CA Canada
Listing CSE LOBE

About Lobe Sciences Ltd.

https://www.lobesciences.com/

Lobe Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for rare and underserved diseases with unmet medical needs. The company utilizes innovative technologies, including lipid technology, to advance its pipeline. Through its subsidiary, Cynaptec Pharmaceuticals, Lobe is developing L-130 (Conjugated Psilocin™), a patented formulation engineered to provide the therapeutic effects of psilocybin without the hallucinogenic properties. Its second subsidiary, Altemia, Inc., develops S-100, a novel medical food product intended for the dietary management and treatment of Sickle Cell Disease. The company's research targets conditions such as Chronic Cluster Headache and Sickle Cell Disease.

Recent filings

Filing Released Lang Actions
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings
2021-12-24 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings
2021-12-24 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings
2021-12-24 English
Annual MD&A - English.pdf
Regulatory Filings
2021-12-24 English
News release - English.pdf
Regulatory Filings
2021-11-16 English
News release - English.pdf
Regulatory Filings
2021-11-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.